RD Sade (RADL3), Brazils largest pharmacy chain, saw its shares plummet 7.9% to R$17.91 ($3.00) on May 7 after reporting weaker-than-expected first-quarter earnings.The operator of DrogaRaia and Drogasil stores posted a 17% annual decline in net income to R$177.1 million ($29.5 million), despite a 10.8% revenue increase to R$10.8 billion ($1.8 billion).Adjusted EBITDA fell 5.3% to R$644 million ($107 million), with margins shrinking to 6% as rising labor costs and aggressive promotions squeezed profitability.
The company burned R$123.8 million ($20.6 million) in free cash flow during the quarter, compounding concerns about its expansion strategy.RD Sade opened 75 new stores, reaching 3,301 locations nationwide, but same-store sales growth slowed to 5.4% from 9.6% a year earlier.
Analysts cited weaker demand for cosmetics and hygiene products as a key drag.They also pointed to fewer dengue fever cases compared to 2024 and calendar effects from the leap year.
Market share edged up 0.4 percentage points to 16.6%, though gains came at the cost of margin erosion.RD Sade Struggles With Profitability in Q1 2025 as Market Share Gains Fail to Offset Costs.
(Photo Internet reproduction)Goldman Sachs maintained a buy rating with a R$25.00 ($4.17) price target, betting on digital investments and a planned 330-350 new stores in 2025.
Conversely, Ita BBA warned of further earnings downgrades, noting net income missed consensus by 23%.RD Sade Faces Margin PressuresBTG Pactual called Q1 a low point but retained its buy recommendation, highlighting RD Sades 2.8% reduction in administrative costs as a rare bright spot.The results arrive as Brazils R$39.3 billion ($6.6 billion) generic drug market grows at 6.4% annually through 2033, driven by patent expirations and government cost-cutting initiatives.However, intensifying competition from online pharmacies and physical rivals threatens RD Sades dominance.
Investors now question whether the firms R$1.22 billion ($203 million) annual free cash flow can sustain both dividend payouts and its aggressive store rollout.Shares have fallen 18% year-to-date, underperforming the Ibovespas 2.5% decline.
With seven analysts rating the stock a buy, seven neutral, and three sell, the divided outlook reflects uncertainty about Brazils pharmaceutical retail sector.RD Sades next challenge: proving its digital platforms and omnichannel strategy can offset margin pressures from government-mandated drug price controls taking effect later this year.